DK1977751T3 - Amorf (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol som middel mod ulcus - Google Patents

Amorf (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol som middel mod ulcus

Info

Publication number
DK1977751T3
DK1977751T3 DK08151945.6T DK08151945T DK1977751T3 DK 1977751 T3 DK1977751 T3 DK 1977751T3 DK 08151945 T DK08151945 T DK 08151945T DK 1977751 T3 DK1977751 T3 DK 1977751T3
Authority
DK
Denmark
Prior art keywords
methyl
trifluoroethoxy
sulfinyl
benzimidazole
pyridinyl
Prior art date
Application number
DK08151945.6T
Other languages
English (en)
Inventor
Akira Fujishima
Isao Aoki
Keiji Kamiyama
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15924444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1977751(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK1977751T3 publication Critical patent/DK1977751T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
DK08151945.6T 1999-06-17 2000-06-15 Amorf (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol som middel mod ulcus DK1977751T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17150999 1999-06-17
EP00937235A EP1129088B1 (en) 1999-06-17 2000-06-15 Crystalline form of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole

Publications (1)

Publication Number Publication Date
DK1977751T3 true DK1977751T3 (da) 2013-09-02

Family

ID=15924444

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00937235T DK1129088T3 (da) 1999-06-17 2000-06-15 Krystallinsk form af (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridin-yl]methyl]sulfinyl]-1H-ben
DK08151945.6T DK1977751T3 (da) 1999-06-17 2000-06-15 Amorf (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol som middel mod ulcus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK00937235T DK1129088T3 (da) 1999-06-17 2000-06-15 Krystallinsk form af (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridin-yl]methyl]sulfinyl]-1H-ben

Country Status (27)

Country Link
US (11) US6462058B1 (da)
EP (3) EP1129088B1 (da)
KR (3) KR100407847B1 (da)
CN (1) CN1150186C (da)
AR (5) AR031069A1 (da)
AT (1) ATE391126T1 (da)
AU (1) AU778820B2 (da)
BE (1) BE2014C017I2 (da)
BR (1) BRPI0011674B8 (da)
CA (1) CA2375201C (da)
CY (2) CY1110384T1 (da)
DE (1) DE60038481T2 (da)
DK (2) DK1129088T3 (da)
ES (2) ES2300265T3 (da)
HK (2) HK1038227A1 (da)
HU (1) HU229067B1 (da)
IL (2) IL145996A0 (da)
MX (1) MXPA01012642A (da)
MY (1) MY125399A (da)
NO (1) NO321168B1 (da)
NZ (1) NZ515702A (da)
PL (1) PL201068B1 (da)
PT (2) PT1129088E (da)
SI (1) SI1129088T1 (da)
TW (2) TWI289557B (da)
WO (2) WO2004083200A1 (da)
ZA (1) ZA200108331B (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
ES2240113T3 (es) * 1999-06-30 2005-10-16 Takeda Pharmaceutical Company Limited Cristales de lansoprazol.
CN1193024C (zh) 2000-04-28 2005-03-16 武田药品工业株式会社 生产旋光的亚砜衍生物的方法
EP1897877B1 (en) 2000-05-15 2014-09-24 Takeda Pharmaceutical Company Limited Crystalline forms of (R)-lanzoprazole
EP1306375B1 (en) 2000-08-04 2006-10-11 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and application thereof
PL399787A1 (pl) * 2000-12-01 2012-11-05 Takeda Pharmaceutical Company Ltd. Krysztaly (R)- lub (S)-2-[[[3-metylo-4-(2,2,2-trifluoroetoksy)-2-pirydynylo]metylo]sulfinylo]-1H-benzimidazolu, kompozycja farmaceutyczna zawierajaca te krysztaly i ich zastosowanie
WO2003032953A1 (fr) 2001-10-17 2003-04-24 Takeda Chemical Industries, Ltd. Granules contenant un agent chimique instable en milieu acide, en concentration elevee
KR100467100B1 (ko) * 2002-03-20 2005-01-24 일양약품주식회사 2-[(4-메톡시-3-메틸)-2-피리디닐]메틸설피닐-5-(1Ｈ-피롤-1-릴)-1Ｈ-벤즈이미다졸 또는 이의 Ｎа염을 함유하는주사제의 제조방법
US20040010151A1 (en) * 2002-03-27 2004-01-15 Nina Finkelstein Lansoprazole polymorphs and processes for preparation thereof
CA2502219C (en) 2002-10-16 2012-05-29 Takeda Pharmaceutical Company Limited A process for producing an amorphous isomer of lansoprazole
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
CN100364987C (zh) 2003-03-24 2008-01-30 卫材R&D管理有限公司 亚砜衍生物或其盐的非定形态的制备方法
US20070101907A1 (en) * 2003-06-20 2007-05-10 Ch Chemical (Pty) Ltd. Liner
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06000524A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulacion farmaceutica y metodo para tratar desordenes gastrointestinales provocados por acido.
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
WO2005117870A2 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8461187B2 (en) * 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
CN102775388B (zh) 2004-09-13 2016-01-20 武田药品工业株式会社 氧化化合物的制备方法和制备装置
CA2784881C (en) 2005-02-25 2016-02-09 Takeda Pharmaceutical Company Limited Method for producing granules
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
JP2009511481A (ja) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
US20090175959A1 (en) 2005-12-28 2009-07-09 Takeda Pharmaceutical Company Limited Controlled Release Solid Preparation
KR100758600B1 (ko) 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20100093804A1 (en) * 2006-12-07 2010-04-15 Hetero Drugs Limited novel crystalline form of lansoprazole
WO2008081891A1 (ja) 2006-12-28 2008-07-10 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤
CN104069088A (zh) * 2007-10-12 2014-10-01 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
WO2009087672A1 (en) * 2007-12-18 2009-07-16 Watson Pharma Private Limited A process for preparation of stable amorphous r-lansoprazole
WO2009088857A1 (en) * 2007-12-31 2009-07-16 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r) -2- [ [ [3-methyl-4- (2, 2, 2-trifluoroethoxy) -2-pyridinyl] methyl] sulfinyl] -1h-benz imidazole
UA103189C2 (ru) * 2008-03-10 2013-09-25 Такеда Фармасьютикал Компани Лимитед Кристаллическая форма бензимидазольного соединения
NZ588407A (en) 2008-03-11 2012-07-27 Takeda Pharmaceutical Orally-disintegrating solid preparation
EP2265605A4 (en) * 2008-03-18 2011-08-03 Reddys Lab Ltd Dr METHOD OF MANUFACTURING DEXLANSOPRAZOLE AND POLYMORPHIDE THEREOF
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
BRPI0912478A2 (pt) 2008-05-14 2016-02-10 Watson Pharma Private Ltd sal de r-(+)-lansoprazol alquilamina, processo para preparar um sal de r-(+)-lansoprazol alquilamina estável e forma de dosagem farmacêutica
TW201431552A (zh) * 2008-07-28 2014-08-16 Takeda Pharmaceutical 醫藥組成物
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
IT1391758B1 (it) * 2008-11-11 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo amorfo
WO2010056059A2 (en) * 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
IT1391776B1 (it) * 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
IT1392813B1 (it) * 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) * 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
ES2712752T3 (es) 2009-11-12 2019-05-14 Pharmatrophix Inc Formas cristalinas de compuestos miméticos de neurotrofina y sus sales
CN102108076B (zh) * 2009-12-23 2014-07-23 江苏豪森医药集团有限公司 制备无定形右兰索拉唑的方法
WO2011092665A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
CA2795110C (en) * 2010-03-31 2015-06-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2011121546A1 (en) 2010-03-31 2011-10-06 Ranbaxy Laboratories Limited Salts of dexlansoprazole and their preparation
EP2384745A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of dexlansoprazole
EP2384747A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Oral Tablet Compositions Of Dexlansoprazole
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
US20130216617A1 (en) 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
CA2819460C (en) 2010-12-03 2017-08-01 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
US20130273157A1 (en) 2010-12-27 2013-10-17 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
EP2663306A4 (en) * 2011-01-12 2014-01-01 Hetero Research Foundation POLYMORPHS OF DEXLANSOPRAZOLE SALTS
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2012111024A1 (en) 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
US20140357870A1 (en) * 2011-06-21 2014-12-04 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN102875530A (zh) * 2011-07-15 2013-01-16 上海睿智化学研究有限公司 一种(r)-兰索拉唑叔丁胺盐及其晶型和制备方法
CN102875531B (zh) * 2011-07-15 2015-08-19 上海睿智化学研究有限公司 一种(r)-兰索拉唑无水晶型及其制备方法
CN102875532B (zh) * 2011-07-15 2015-05-13 上海睿智化学研究有限公司 一种(r)-兰索拉唑异丙胺盐及其晶型和制备方法
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
AR089032A1 (es) 2011-11-30 2014-07-23 Takeda Pharmaceutical Comprimido recubierto seco
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
CN103709139B (zh) * 2012-10-09 2016-12-21 上海汇伦生命科技有限公司 无水右兰索拉唑的制备方法
CN104177333A (zh) * 2013-05-24 2014-12-03 四川海思科制药有限公司 一种理化性质稳定的(r)-2-[[[3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基]甲基]亚磺酰基]-1h-苯并咪唑
CN104650035A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 右兰索拉唑倍半水合物化合物
CN103664889B (zh) * 2013-12-19 2014-11-19 悦康药业集团有限公司 一种兰索拉唑化合物
EP2929885A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
EP2933002A1 (en) 2014-04-11 2015-10-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
CN104844576B (zh) * 2015-04-28 2017-03-08 山东罗欣药业集团股份有限公司 一种兰索拉唑或右旋兰索拉唑晶型化合物及其制备方法
CN104829594A (zh) * 2015-05-15 2015-08-12 苗怡文 一种治疗胃溃疡的药物兰索拉唑化合物
CN105017218A (zh) * 2015-07-01 2015-11-04 合肥安德生制药有限公司 一种右兰索拉唑晶型及其制备方法
CN104958276A (zh) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物兰索拉唑组合物胶囊
CN104997738A (zh) * 2015-08-10 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃病的药物兰索拉唑组合物干混悬剂
CN105399728B (zh) * 2015-12-20 2017-11-28 寿光富康制药有限公司 一种适用于工业化生产的右兰索拉唑的处理方法
CN108164507A (zh) * 2016-12-07 2018-06-15 天津药物研究院有限公司 一种右兰索拉唑单晶及其制备方法和用途
TR201701461A2 (tr) 2017-01-31 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dekslansoprazolün Enterik Kaplı Farmasötik Kompozisyonları
CN106866630B (zh) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 一种右兰索拉唑的制备方法
CN107011329A (zh) * 2017-05-05 2017-08-04 广州大光制药有限公司 兰索拉唑一水合物晶型及其结晶制备方法
CN108794450B (zh) * 2018-07-24 2022-08-19 浙江恒康药业股份有限公司 制备无定型右旋兰索拉唑的方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
WO1998021207A1 (de) 1996-11-12 1998-05-22 Byk Gulden Lomberg Chemische Fabrik Gmbh (2,3-dihydrobenzofuranyl)-thiazole als phosphodiesterasehemmer
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
WO1998022118A1 (en) * 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
AU742620B2 (en) 1998-01-30 2002-01-10 Sepracor, Inc. R-lansoprazole compositions and methods
CA2320902A1 (en) 1998-01-30 1999-08-05 Sepracor, Inc. S-lansoprazole compositions and methods
AU3596199A (en) * 1998-05-06 1999-11-23 Kobenhavns Universitet Treatment of celiac disease
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
ES2240113T3 (es) * 1999-06-30 2005-10-16 Takeda Pharmaceutical Company Limited Cristales de lansoprazol.
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法
CA2502219C (en) * 2002-10-16 2012-05-29 Takeda Pharmaceutical Company Limited A process for producing an amorphous isomer of lansoprazole
CN100364987C (zh) * 2003-03-24 2008-01-30 卫材R&D管理有限公司 亚砜衍生物或其盐的非定形态的制备方法
CA2591983A1 (en) * 2004-12-20 2006-06-29 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising amorphous benzimidazole compounds
EP1830823A2 (en) * 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
WO2009087672A1 (en) * 2007-12-18 2009-07-16 Watson Pharma Private Limited A process for preparation of stable amorphous r-lansoprazole

Also Published As

Publication number Publication date
DK1129088T3 (da) 2008-06-09
PT1129088E (pt) 2008-05-05
US8030333B2 (en) 2011-10-04
CY1110384T1 (el) 2015-04-29
EP1129088A2 (en) 2001-09-05
US7339064B2 (en) 2008-03-04
AR079473A2 (es) 2012-01-25
HK1038227A1 (en) 2002-03-08
US20100222391A1 (en) 2010-09-02
US9145389B2 (en) 2015-09-29
ES2426985T3 (es) 2013-10-28
HUP0201659A2 (hu) 2002-11-28
PL201068B1 (pl) 2009-03-31
AR031069A1 (es) 2003-09-10
CY1114485T1 (el) 2017-01-25
SI1129088T1 (sl) 2008-08-31
NO321168B1 (no) 2006-03-27
CN1150186C (zh) 2004-05-19
WO2004083200A1 (en) 2004-09-30
WO2000078745A3 (en) 2001-07-05
KR100514204B1 (ko) 2005-09-13
DE60038481T2 (de) 2009-04-09
US6939971B2 (en) 2005-09-06
US7569697B2 (en) 2009-08-04
KR20010071354A (ko) 2001-07-28
TWI275587B (en) 2007-03-11
US6664276B2 (en) 2003-12-16
AR100473A2 (es) 2016-10-12
ZA200108331B (en) 2002-10-10
NO20016087D0 (no) 2001-12-13
HUP0201659A3 (en) 2003-11-28
CN1355798A (zh) 2002-06-26
HK1123985A1 (en) 2009-07-03
MXPA01012642A (es) 2002-07-22
US8552198B2 (en) 2013-10-08
BRPI0011674B1 (pt) 2017-05-30
AU5247800A (en) 2001-01-09
ATE391126T1 (de) 2008-04-15
AU778820B2 (en) 2004-12-23
US20080132547A1 (en) 2008-06-05
PL352193A1 (en) 2003-08-11
US20030045724A1 (en) 2003-03-06
CA2375201A1 (en) 2000-12-28
WO2000078745A2 (en) 2000-12-28
EP1129088B1 (en) 2008-04-02
US7737282B2 (en) 2010-06-15
US6462058B1 (en) 2002-10-08
ES2300265T3 (es) 2008-06-16
KR20030068592A (ko) 2003-08-21
US20040048898A1 (en) 2004-03-11
KR20010052467A (ko) 2001-06-25
HU229067B1 (en) 2013-07-29
BRPI0011674B8 (pt) 2021-05-25
TWI289557B (en) 2007-11-11
EP1977751A1 (en) 2008-10-08
KR100537029B1 (ko) 2005-12-16
US20140012006A1 (en) 2014-01-09
EP1977751B1 (en) 2013-07-24
US20110319450A1 (en) 2011-12-29
DE60038481D1 (de) 2008-05-15
US20050228026A1 (en) 2005-10-13
AR093609A2 (es) 2015-06-10
IL145996A (en) 2008-07-08
US20150025115A1 (en) 2015-01-22
US20090163553A1 (en) 2009-06-25
BE2014C017I2 (da) 2019-05-21
US20120316344A1 (en) 2012-12-13
PT1977751E (pt) 2013-08-01
BR0011674A (pt) 2002-03-19
EP2343289A1 (en) 2011-07-13
MY125399A (en) 2006-07-31
AR103295A2 (es) 2017-05-03
CA2375201C (en) 2010-02-09
NZ515702A (en) 2003-07-25
NO20016087L (no) 2001-12-13
KR100407847B1 (ko) 2003-12-01
US8884019B2 (en) 2014-11-11
IL145996A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
DK1977751T3 (da) Amorf (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol som middel mod ulcus
DK1175402T3 (da) Piperidinderivater, der er nyttige som CCR5-antagonister
NO1995006I1 (no) Omeprazole/ 5-metoksy-2-[[(4-metoksy-3,5-dimetyl-2-pyridinyl)metyl]sulfinyl]-1H-benzimidazol
DK1049689T3 (da) 4-(2-keto-1-benzimidazolinyl)piperidinderivater som ORL1-receptoragonister
EP2292612A3 (en) Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
NO20026125L (no) Tetrahydropyridin- eller piperidin-heterocykliske derivater
EP1191025A4 (en) CRYSTALS OF BENZIMIDAZOLE DERIVATIVES
NO20041235L (no) Kinolinderivater som neuropeptid Y antagonister
ZA200500065B (en) Crystalline 2,5,-dione-3-(1-methyl-1H-indol-3-yl)-Ä1-(pyridin-2-ylmethyl)piperidin-4-ylÜ-1H-indol-3-ylÜ-1H-pyrrole mono-hydrochloride
ZA989999B (en) New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole
DE60114852D1 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
DE60038911D1 (de) 4-Phenylpiperazinyl, -piperidinyl und -tetrahydropyridyl-Derivate als Dopamin D4-Antagonisten
AU2000258410A1 (en) New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole
DE50010821D1 (de) Abklappbarer wischarm
DK1231211T3 (da) Thiazolidindion-derivater som antidiabetika
ID28645A (id) KOMPOSISI-KOMPOSISI ORAL 8-KLORO-6, 11-DIHIDRO-11-(4-PIPERIDILIDENA)- 5H-BENZO(5,6) SIKLOHEPTA (1,2-b) PIRIDINA
NO20026104L (no) Heterosykliske aminoalkylpyridinderivater som psykofarmaka
ATE315025T1 (de) Ethansulfonyl-piperidin-derivate
BR0015220A (pt) Procedimento melhorado para a preparação de derivados de benzimidazol adequados como fármacos antiulcerosos, principalmente omeprazol ou pantoprazol
NO20042946L (no) Piperidin-2,6-dioner som er heterocyklisk substituert i posisjon 3
ECSP003736A (es) Procedimiento mejorado para la preparacion de derivados de bencimidazol adecuados como farmacos antiulcerosos, particularmente omeprazol o pantoprazol
UY26420A1 (es) Procedimiento mejorado para la preparación de derivados bencimidazol adecuados como fármacos antiulcerosos, particularmente omeprazol o pantoprazol
KR100463031B1 (ko) 5-메톡시-2-[3,5-디메틸-4-메톡시피리딜메틸)설피닐]-1h-벤즈이미다졸의신규제조방법
TH69761B (th) ผลึกสารประกอบเบนซิมิแดซอล
NO20000222D0 (no) Munnstykke for mudringsarm